

James Goodhand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8671006/publications.pdf>

Version: 2024-02-01

60
papers

3,011
citations

201674

27
h-index

214800

47
g-index

65
all docs

65
docs citations

65
times ranked

3682
citing authors

#	ARTICLE	IF	CITATIONS
1	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 389-397.	1.3	39
2	P196 Pre-treatment antibodies to infliximab and adalimumab are common but are not associated with anti-TNF treatment failure. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i256-i256.	1.3	0
3	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 342-352.	8.1	100
4	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. <i>Nature Communications</i> , 2022, 13, 1379.	12.8	48
5	Understanding <sc>anti-TNF</sc> treatment failure: does serum triiodothyronine-to-thyroxine (<sc>T3</sc>/<sc>T4</sc>) ratio predict therapeutic outcome to <sc>anti-TNF</sc> therapies in biologic-naïve patients with active luminal Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 783-793.	3.7	5
6	Incidence and prevalence of inflammatory bowel disease in Devon, UK. <i>Frontline Gastroenterology</i> , 2021, 12, 461-470.	1.8	18
7	P92...Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multi-centre UK experience. , 2021, , .		0
8	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021, 70, 865-875.	12.1	153
9	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. <i>Gut</i> , 2021, 70, 1884-1893.	12.1	233
10	P387 Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S398-S399.	1.3	0
11	Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 128-137.	3.7	9
12	OFR-8...Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. , 2021, , .		2
13	Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 291-301.	3.7	5
14	Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease—getting to the root. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 337-338.	3.7	1
15	Jejunal perforation and central retinal vein occlusion in a 55-year-old European man. <i>Gut</i> , 2020, 69, 73-111.	12.1	0
16	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 189-199.	1.3	249
17	Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. <i>Archives of Disease in Childhood</i> , 2020, 105, 957-963.	1.9	4
18	Quality improvement project identifies factors associated with delay in IBD diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 471-480.	3.7	14

#	ARTICLE	IF	CITATIONS
19	Genetic evidence that higher central adiposity causes gastro-oesophageal reflux disease: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2020, 49, 1270-1281.	1.9	20
20	Massively parallel variant characterization identifies <i>NUDT15</i> alleles associated with thiopurine toxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 5394-5401.	7.1	95
21	DOP69 Tofacitinib in ulcerative colitis: Early "real-world" experience from four UK tertiary centres. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S106-S106.	1.3	0
22	Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1385-1393.	1.3	74
23	DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn's disease: A pilot serum proteomic analysis of the PANTS cohort. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S067-S068.	1.3	3
24	Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for rollout?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1076-1077.	3.7	1
25	Factors associated with depression in people with inflammatory bowel disease: The relationship between active disease and biases in neurocognitive processing. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13647.	3.0	14
26	Genome-Wide Association Study of Microscopic Colitis in the UK Biobank Confirms Immune-Related Pathogenesis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1578-1582.	1.3	32
27	Predictors of anti-TNF treatment failure in anti-TNF-naïve patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 341-353.	8.1	431
28	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	7.4	129
29	PWE-010...Introduction of a primary care dietetics service for functional gut disorders. , 2019, , .		0
30	PTU-108...Prospective cohort to identify factors associated with diagnostic delay in patients with inflammatory bowel disease. , 2019, , .		0
31	Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1103-1116.	3.7	31
32	PTU-010...Prevalence and phenotype of IBD across primary and secondary care: implications for colorectal cancer surveillance. , 2018, , .		0
33	Haemosuccus pancreaticus. <i>BMJ: British Medical Journal</i> , 2017, , i6446.	2.3	2
34	Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 660-669.	3.7	96
35	Editorial: which iron preparation for patients with IBD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 194-195.	3.7	6
36	Oral Iron Treatment Response and Predictors in Anaemic Adolescents and Adults with IBD: A Prospective Controlled Open-Label Trial. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw208.	1.3	13

#	ARTICLE	IF	CITATIONS
37	How can we improve models of care in inflammatory bowel disease? An international survey of IBD health professionals. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1668-1674.	1.3	47
38	The dangers of living in a tent in London. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013201654-bcr2013201654.	0.5	3
39	Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNF \pm therapy. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 412-418.	1.3	20
40	Weight loss and lumbosacral back pain in a 79-year-old Indian man. <i>Gut</i> , 2013, 62, 1504-1504.	12.1	0
41	Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1097-1108.	3.7	65
42	Factors Associated With Nonadherence to Thiopurines in Adolescent and Adult Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 685-689.	1.8	21
43	PTU-163–Depression and carcinoid syndrome: is there any relationship? A cross-sectional study. <i>Gut</i> , 2012, 61, A252.1-A252.	12.1	0
44	Do Antidepressants Influence the Disease Course in Inflammatory Bowel Disease? A Retrospective Case-Matched Observational Study. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1232-1239.	1.9	99
45	Integrated Models of Care in Managing Inflammatory Bowel Disease: A Discussion. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1582-1587.	1.9	51
46	Mood disorders in inflammatory bowel disease: Relation to diagnosis, disease activity, perceived stress, and other factors. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2301-2309.	1.9	183
47	The phenotype and course of inflammatory bowel disease in <sc>UK</sc> patients of <sc>B</sc>angladeshi descent. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 929-940.	3.7	20
48	Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 513-519.	1.9	117
49	Adolescents with IBD: The importance of structured transition care. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 509-519.	1.3	99
50	Anxiety and Psychological Stress in Acute Severe Ulcerative Colitis: Prevalence and Effect on Outcome. <i>Gastroenterology</i> , 2011, 140, S-60-S-61.	1.3	1
51	Tobacco dependence and awareness of health risks of smoking in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 90-94.	1.6	12
52	Do Children With IBD Really Respond Better Than Adults to Thiopurines?. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 52, 702-707.	1.8	10
53	Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1029-1035.	1.6	35
54	Systematic review: <i>Clostridium difficile</i> and inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 428-441.	3.7	102

#	ARTICLE	IF	CITATIONS
55	Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 551-558.	3.7	27
56	Poster presentations at medical conferences: an effective way of disseminating research?. <i>Clinical Medicine</i> , 2011, 11, 138-141.	1.9	36
57	Does psychological counseling alter the natural history of inflammatory bowel disease?. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 664-669.	1.9	55
58	Inflammatory bowel disease in young people. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 947-952.	1.9	87
59	Management of stress in inflammatory bowel disease: a therapeutic option?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 661-679.	3.0	46
60	Psychological stress and coping in IBD. <i>Gut</i> , 2008, 57, 1345-1347.	12.1	23